MedTrace Logo

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

NCT02848326 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 834

Last updated 2018-12-06

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship.

Conditions

  • Migraine, With or Without Aura

Interventions

DRUG

Atogepant

Atogepant capsule.

DRUG

Placebo-matching Atogepant

Placebo-matching atogepant capsule.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Joel Trugman, MD · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-06
Primary Completion
2018-04-02
Completion
2018-04-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02848326 on ClinicalTrials.gov